Johnson & Johnson (JNJ) Stock Price, Trades & News

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.

Financial Strength

7/10

Name	Current	Vs Industry
Cash-To-Debt	0.4
Equity-to-Asset	0.4
Debt-to-Equity	0.68
Debt-to-EBITDA	1.71
Interest Coverage	33.11
Piotroski F-Score	4/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	4.04	Distress Grey Safe
Beneish M-Score	-2.08	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

8/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	8.9
	3-Year EBITDA Growth Rate	19.2
	3-Year EPS without NRI Growth Rate	2.1
	3-Year FCF Growth Rate	7.2
	3-Year Book Growth Rate	4.8
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	9.59
	Future 3-5Y Total Revenue Growth Rate Estimate	7.29

Momentum Rank

3/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	73.95
	9-Day RSI	65.21
	14-Day RSI	62.64
	3-1 Month Momentum %	5.93
	6-1 Month Momentum %	9.48
	12-1 Month Momentum %	42.13

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	1.03
	Quick Ratio	0.77
	Cash Ratio	0.38
	Days Inventory	160.25
	Days Sales Outstanding	64.39
	Days Payable	118.66

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Yield %	1.97
	Dividend Payout Ratio	0.5
	3-Year Dividend Growth Rate	4.9
	Forward Dividend Yield %	2.02
	5-Year Yield-on-Cost %	2.55
	3-Year Average Share Buyback Ratio	2.7
	Shareholder Yield %	1.96

Profitability Rank

8/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	67.91
	Operating Margin %	26.81
	Net Margin %	21.48
	EBITDA Margin %	32.83
	FCF Margin %	22.7
	OCF Margin %	28.19
	ROE %	26.39
	ROA %	10.73
	ROIC %	14.43
	3-Year ROIIC %	64.04
	ROC (Joel Greenblatt) %	118.08
	ROCE %	18.66
	Years of Profitability over Past 10-Year	10
	Moat Score	9
	Tariff Resilience Score	8

GF Value Rank

5/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	30.52
	Forward PE Ratio	22.53
	PE Ratio without NRI	25.16
	Shiller PE Ratio	33.09
	Price-to-Owner-Earnings	38.27
	PEG Ratio	2.68
	PS Ratio	6.54
	PB Ratio	7.81
	Price-to-Free-Cash-Flow	36.78
	Price-to-Operating-Cash-Flow	28.08
	EV-to-EBIT	25.45
	EV-to-Forward-EBIT	20.8
	EV-to-EBITDA	19.64
	EV-to-Forward-EBITDA	17.37
	EV-to-Revenue	6.81
	EV-to-Forward-Revenue	6.5
	EV-to-FCF	30.01
	Price-to-GF-Value	1.37
	Price-to-Projected-FCF	2.41
	Price-to-DCF (Earnings Based)	2.12
	Price-to-DCF (FCF Based)	3.19
	Price-to-Median-PS-Value	1.38
	Price-to-Peter-Lynch-Fair-Value	2.41
	Earnings Yield (Greenblatt) %	3.93
	FCF Yield %	3.51
	Forward Rate of Return (Yacktman) %	13.27

Financials (Next Earnings Date:2026-10-13)

Annual Quarterly TTM

JNJ's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Johnson & Johnson Operating Data

Annual Quarterly

JNJ's Complete Operating Data

No operating data available for Johnson & Johnson.

Guru Trades

See Details

Insider Trades

See Details

Gurus Latest Trades with NYSE:JNJ

No Available Data

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Johnson & Johnson Executives

Details

GF Value™: $191.57

JNJ

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 7 Medium warning signs with JNJ. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil $)	97,929
	EPS (TTM) ($)	8.63
	Beta	0.0706
	3-Year Sharpe Ratio	0.63
	3-Year Sortino Ratio	1.16
	Volatility %	20.67
	14-Day RSI	62.64
	14-Day ATR ($)	5.964579
	20-Day SMA ($)	256.4795
	12-1 Month Momentum %	42.13
	52-Week Range ($)	164.23 - 269.43
	Shares Outstanding (Mil)	2,409.9

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	4
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Johnson & Johnson Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Johnson & Johnson Stock Events

Financials Calendars

Event	Date	Price ($)
Fourth quarter earnings results for 2026	2027-01-21 18:45	In 182 days
Fourth quarter earnings conference call for 2026	2027-01-21 08:30	In 181 days
Third quarter earnings conference call for 2026	2026-10-13	In 80 days
Third quarter earnings results for 2026	2026-10-13	In 80 days
USD 1.340000 Cash Dividend	2026-08-25	In 31 days
Second quarter earnings conference call for 2026	2026-07-15 08:30	253.85 (-0.66%)
Second quarter earnings results for 2026	2026-07-15 06:45	253.85 (-0.66%)
Goldman Sachs 47th Annual Global Healthcare Conference	2026-06-09 10:00	232.16 (-0.26%)
Bernstein’s 42nd Annual Strategic Decisions Conference	2026-05-27 11:00	230.18 (-1.21%)
USD 1.340000 Cash Dividend	2026-05-26	234.34 (+0.58%)

Show

Entries

Johnson & Johnson Frequently Asked Questions

What is Johnson & Johnson(JNJ)'s stock price today?

The current price of JNJ is $263.40. The 52 week high of JNJ is $269.43 and 52 week low is $164.23.

When is next earnings date of Johnson & Johnson(JNJ)?

The next earnings date of Johnson & Johnson(JNJ) is 2026-10-13.

Does Johnson & Johnson(JNJ) pay dividends? If so, how much?

The Dividend Yield % of Johnson & Johnson(JNJ) is 1.97% (As of Today), Highest Dividend Payout Ratio of Johnson & Johnson(JNJ) was 0.5. The lowest was 0.43. And the median was 0.46. The Forward Dividend Yield % of Johnson & Johnson(JNJ) is 2.02%. For more information regarding to dividend, please check our Dividend Page.

Guru Commentaries on NYSE:JNJ

Fidelity Strategic Dividend & Income Fund, Q3 2024 Fund Letter

Madison Dividend Income Fund Q3 2024 Fund Letter

Madison Dividend Income Fund, Q1 2024 Fund Letter

Press Release

	Subject	Date
	TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma	2026-07-23
	Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System	2026-07-22
	Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award	2026-07-16
	DePuy Synthes Acquires Expanding Innovations™	2026-07-16
	Johnson & Johnson reports Q2 2026 results, raises 2026 outlook	2026-07-15
	Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026	2026-07-15
	Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform	2026-07-08
	Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis	2026-06-26
	Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida	2026-06-15
	New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myel	2026-06-13

10/Page

Articles on Johnson & Johnson

JNJ

JNJ SWOT Analysis: Key Insights from the 10-Q Filing

1 day ago

JNJ

TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma

1 day ago

JNJ

Johnson & Johnson's (JNJ) MonumenTAL-6 Study Shows Promising Results

1 day ago

JNJ

10-Q - JOHNSON & JOHNSON (0000200406)

2 days ago

JNJ

Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System

3 days ago

Headlines

Jul 24, 2026

J&J, Gilead among recipients of EU drug recommendations this week

Seeking Alpha • 9:54am

These mega caps are trading in overbought territory as earnings season heats up

Seeking Alpha • 6:48am

Jul 23, 2026

Palisade Bio jumps following Oppenheimer outperform initiation

Seeking Alpha • 10:13am

Jul 22, 2026

J&J wins FDA nod for Ottava surgical robot

Seeking Alpha • 7:35am

Jul 19, 2026

Notable healthcare headlines for the week: UnitedHealth, J&J, and Intuitive Surgical in focus

Seeking Alpha • 8:05am

Jul 15, 2026

Midday Need to Know: J&J beats estimates, PPI drops & more

Seeking Alpha • 10:53am

Earnings Snapshot: Johnson & Johnson Q2 beats on top and bottom lines, hikes FY2026 guidance

Seeking Alpha • 6:12am

Johnson & Johnson declares $1.34 dividend

Seeking Alpha • 5:34am

Johnson & Johnson beats top-line and bottom-line estimates; raises FY26 outlook

Seeking Alpha • 5:23am

Jul 14, 2026

Here are the major earnings before the open Wednesday

Seeking Alpha • 5:00pm

Johnson & Johnson: Analysts see upbeat Q2 print despite Stelara headwinds

Seeking Alpha • 11:49am

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.